SCM
REGN icon

Superstring Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Superstring Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,401
Closed -$3.6M – 58
2025
Q3 		$3.6M Buy
+6,401
New +$3.62M 3.55% 13

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Superstring Capital Management's REGN Position: Q4 2025 in Review

Superstring Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 6,401 shares — an estimated $3.6M sold.

Superstring Capital Management first reported a position in REGN in Q3 2025 and held it in 1 quarter. The position peaked at $3.6M in Q3 2025. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Superstring Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Superstring Capital Management sold 6,401 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $3.6M.
  • Superstring Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Superstring Capital Management's Regeneron Pharmaceuticals position peaked at $3.6M in Q3 2025.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Superstring Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.